Drug Trial Radar · NCT00900146
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
Last checked: Nov 20, 2026Latest source record: Feb 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
556
Actual
Start
Apr 2009
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 12, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.
Conditions
- Diabetes Mellitus, Type 2
Interventions
CanakinumabDrug
Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
MetforminDrug
Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
PlaceboDrug
Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events, Death and Clinical Significant AEs During 4 Months (Period II)Time frame: 4 months (Period II)
- Change From Baseline in Hemoglobin A1c (HbA1c) at Month 4 During Dose-finding Period of the Study (Period II)Time frame: Baseline, Month 4
- Change From Baseline in Dynamic Phase Secreted Insulin Per Unit of Glucose Concentration (Φd) Over 4 Months (Period III)Time frame: Baseline, Over Month 4
Locations
106 sites in 14 countries. Site status is shown where the registry gives one.
Anasazi Internal Medicine
Phoenix, Arizona
Whittier Institute of Diabetes
La Jolla, California
Novartis Investigative Site
Los Gatos, California
Novartis Investigative Site
Santa Monica, California
Orange County Research Center
Tustin, California
Novartis Investigative Site
Atlanta, Georgia
Deaconess Clinic
Evansville, Indiana
Novartis Investigative Site
Jackson, Mississippi
Novartis Investigative Site
Picayune, Mississippi
Novartis Investigative Site
Trenton, New Jersey
Diabetes Research Center
Columbus, Ohio
Tri-State Medical Group
Beaver, Pennsylvania
Preferred Primary Care Physicians
Pittsburgh, Pennsylvania
Novartis Investigative Site
Columbia, South Carolina
R/D Clinical Research
Lake Jackson, Texas
Novartis Investigative Site
Pasadena, Texas
Novartis Investigative Site
San Antonio, Texas
Medical Research Initiatives Inc
Virginia Beach, Virginia
Novartis Investigative Site
Rosario Santa Fe, Argentina
DIM Clinica Privada
Buenos Aires, Buenos Aires, Argentina
Centro Medico Viamonte
Buenos Aires, Buenos Aires, Argentina
Consultorios Asociados de Endocrinologia
Buenos Aires, Buenos Aires, Argentina
Clinica de Fracturas y Ortopedia
Mar del Plata, Buenos Aires, Argentina
Hospital Juan Ramon Vidal
Corrientes, Corrientes Province, Argentina
Instituto de Investigaciones Biomedicas
Santa Fe, Santa Fe Province, Argentina
Centro de Investigaciones Clinicas del Litoral
Santa Fe, Santa Fe Province, Argentina
Private Practice - DEMEULEMEESTER
Gozée, Belgium
Novartis Investigative Site
Heist-op-den-Berg, Belgium
UZ Brussel
Jette, Belgium
Novartis Investigative Site
Hong Kong, China
Praxis F. Franzmann
Bad Oeynhausen, Germany
emovis GmbH
Berlin, Germany
Praxis Dr. Stütz
Bretten, Germany
GWT-TUB GmbH
Dresden, Germany
Gemeinschaftspraxis und Dialysezentrum Karlstraße
Düsseldorf, Germany
Asklepios Klinik St. Georg
Hamburg, Germany
Städt. Kankenhaus Nordstadt
Hanover, Germany
Diabeteszentrum Hohenmölsen
Hohenmölsen, Germany
Johannes Gutenberg-Universität Mainz
Mainz, Germany
Zentrum für Klinische Forschung Neuwied (ZKSN)
Neuwied, Germany
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.